From 13 till 17 September 2024: HIGHLIGHTS FROM ESMO
Your direct line with Barcelona
The European Society of Medical Oncology (ESMO) 2024 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Barcelona, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
Presidential highlights
Dr Elisa Agostinetto, medical oncologist at Institut Jules Bordet in Brussels, discussed with Dr Sofia Rivera, a radiation oncologist at Institut Gustave Roussy, France the outcomes of the HypoG-01 phase
Arguably one of the most anticipated presentations at ESMO 2024 featured the overall survival (OS) data of the pivotal phase III KEYNOTE-522 trial. Based on a convincing benefit in event-free
Daily highlights in breast cancer
Dr Laure-Anne Teuwen, a medical oncologist at the University Hospital of Antwerp, provided insights from the second mini oral session on metastatic breast cancer at ESMO 2024.
In this video, Dr Kevin Punie discusses and comments on the data of some exciting studies presented at ESMO 2024 during the Mini Oral session on metastatic breast cancer.
In this video, Dr Elisa Agostinetto discusses and comments on the data of some interesting studies presented at ESMO 2024 during the proffered paper session on early-stage breast cancer.
In this video, Dr Françoise Derouane, a medical oncologist at the University Hospitals Leuven, discusses a selection of abstracts presented during the proffered paper session on metastatic breast cancer during
In this video, Dr Eline Naert, medical oncologist at the University hospital Ghent discusses a selection of abstracts that were presented during the mini oral session on early-stage breast cancer
In-depth stories about breast cancer
In this video, Prof Lise-Marie Kinnaer discusses and comments on the data from a study she presented during the annual meeting of the European Oncology Nursing Society.(EONS 2024)
For his presentation at ESMO 2024, Prof Dr Gabriele Zoppoli (University of Genoa and IRCCS Policlinico San Martino, Genoa, Italy) used data from the AURORA trial to evaluate the impact
In this video, Dr Eline Naert (Ghent University Hospital) and Dr Véronique D’Hondt (Centre Régional du Cancer, Montpellier, France) talks us through the key take aways from this presentation.
In this video, Dr Elisa Agostinetto and Dr Maria Fernanda Mosele discuss new biomarker data of this trial.
The presented biomarker analyses of the DAISY trial specifically looked for associations
In this video Dr Elisa Agostinetto, medical oncologist at the Institut Jules Bordet in Brussels and Prof Dr Virginia Kaklamani (UT Health San Antonio, TX, USA) discuss the contemporary treatment
In this video Dr Elisa Agostinetto and Prof Dr Michail Ignatiadis, both medical oncologist at the Institut Jules Bordet in Brussels, discuss the rationale and design of the phase III
Dr Elisa Agostinetto, a medical oncologist at Institut Jules Bordet in Brussels, discussed with Dr Alex De Caluwé, a radiation oncologist also working at the Institut Jules Bordet, the outcomes
Dr Elisa Agostinetto, a medical oncologist at Institut Jules Bordet in Brussels, discusses with Prof Dr Giuseppe Viale, a pathologist working at the European Institute of Oncology in Milan, Italy
Breast cancer poster selection
In a poster presented at ESMO 2024, Dr Guilherme Nader-Marta (Dana Farber Cancer Institute, Boston, MA, USA) shared the results of a retrospective study evaluating the prognostic value of a
In this video, Dr Guilherme Nader-Marta (Dana Farber Cancer Institute, Boston, MA, USA) summarizes the key take-aways from this study.
In this video, Dr Garcia shares the key take-aways of this research with Dr Elisa Agostinetto (Institut Jules Bordet, Brussels, Belgium).
In this video, Dr Carausu shares the key take-aways from these investigations with Dr Elisa Agostinetto (Institut Jules Bordet, Brussels, Belgium).
During ESMO 2022, Prof Dr Naoto Ueno (University of Hawaii Cancer Center, Honolulu, HI, USA) presented the results of an exploratory biomarker analysis of the phase III DESTINY-Breast04 trial.
During ESMO 2024, Dr Eva Ciruelos, medical oncologist at the Hospital Universitario 12 de Octubre in Madrid presented the results of the phase Ib part of the ELECTRA trial. This
Made possible with the financial support of our partners.
All videos are developed independently and are non-promotional.
